These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8549349)

  • 21. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects.
    Meyerhoff C; Dilger C; Yoon SJ; Chung YH; Lee DK; Lee CW; Ryu JM; Choi MS; Pabst G; Reh C
    J Antimicrob Chemother; 1998 Sep; 42(3):349-61. PubMed ID: 9786475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.
    Park YH; Jung BH; Chung BC; Park J; Mitoma C
    Drug Metab Dispos; 1997 Sep; 25(9):1101-3. PubMed ID: 9311628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
    Sato A; Kitazawa H; Chida K; Hayakawa H; Iwata M
    Drugs; 1995; 49 Suppl 2():253-5. PubMed ID: 8549321
    [No Abstract]   [Full Text] [Related]  

  • 24. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.
    Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K
    Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373
    [No Abstract]   [Full Text] [Related]  

  • 26. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 27. Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116.
    Tanimura H; Uchiyama K; Kashiwagi H
    Drugs; 1995; 49 Suppl 2():341-3. PubMed ID: 8549355
    [No Abstract]   [Full Text] [Related]  

  • 28. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat.
    Sasabe H; Terasaki T; Tsuji A; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Jul; 282(1):162-71. PubMed ID: 9223551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.
    Meinen JB; McClure JT; Rosin E
    Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 32. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.
    Cook PJ; Andrews JM; Wise R; Honeybourne D; Moudgil H
    J Antimicrob Chemother; 1995 Feb; 35(2):317-26. PubMed ID: 7759395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
    Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
    [No Abstract]   [Full Text] [Related]  

  • 34. Temafloxacin: the pharmacokinetic profile of a new quinolone. A seminar-in-print.
    Clin Pharmacokinet; 1992; 22 Suppl 1():1-107. PubMed ID: 1319864
    [No Abstract]   [Full Text] [Related]  

  • 35. Quinolones in dermatology.
    Sable D; Murakawa GJ
    Dis Mon; 2004 Jul; 50(7):381-94. PubMed ID: 15280869
    [No Abstract]   [Full Text] [Related]  

  • 36. New generations of quinolones: with particular attention to levofloxacin.
    Ambrose PG; Owens RC; Quintiliani R; Nightingale CH
    Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
    Ozaki M; Tomii Y; Matsuda M; Segawa J; Kitano M; Kise M; Nishino T
    Chemotherapy; 1998; 44(1):21-30. PubMed ID: 9444405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat.
    Sasabe H; Kato Y; Terasaki T; Tsuji A; Sugiyama Y
    Biopharm Drug Dispos; 1999 Apr; 20(3):151-8. PubMed ID: 10211868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
    Iakovlev SV
    Urologiia; 2002; (1):11-4. PubMed ID: 11877963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of enrofloxacin after single intravenous and intramuscular administration in young domestic ostrich (Struthio camelus).
    de Lucas JJ; Rodríguez C; Waxman S; González F; de Vicente ML; San Andrés MI
    J Vet Pharmacol Ther; 2004 Apr; 27(2):119-22. PubMed ID: 15096111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.